Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 25, 2026
Why Is Tradr 2X Long CRDO Daily ETF (CRDU) Up +15.55% Today?

Why Is Tradr 2X Long CRDO Daily ETF (CRDU) Up +15.55% Today?

Key Takeaways

  • CRDU surged 15.55% intraday to about $10.70, up from a prior close of $9.26.
  • The move tracked a roughly 7.6% rally in underlying Credo Technology Group (CRDO), amplified by the fund's 2x daily leverage.
  • Primary catalyst: broad strength across optical-connectivity and silicon-photonics names tied to the AI data center buildout.
  • Secondary drivers: bullish analyst initiations on silicon photonics and co-packaged optics, plus momentum from the ECOC 2026 optical conference.
  • Credo's fundamentals, including 114.7% year-over-year revenue growth in its latest quarter, reinforced investor sentiment.
  • Investors are watching AI capital-expenditure trends, 1.6T optical ramp timing, and customer-concentration risk.

Opening Summary

The Tradr 2X Long CRDO Daily ETF (CRDU) is a leveraged single-stock fund that seeks daily investment results, before fees and expenses, corresponding to two times (200%) the daily performance of Credo Technology Group Holding Ltd (CRDO), a provider of high-speed connectivity and optical interconnect solutions for AI data centers. In today's session, CRDU climbed 15.55% to roughly $10.70, versus a prior closing price of $9.26, as a sharp rally in the underlying CRDO shares translated into an outsized gain through the fund's 2x leverage.

What Drove the ETF Move Today

Sector Momentum in Optical Connectivity

The move was sector-driven. Optical-communication and silicon-photonics stocks rallied broadly, with names such as Viavi Solutions, Tower Semiconductor (TSEM), MaxLinear, GlobalFoundries, and Credo Technology all trading higher. This group has become a focal point for investors betting that the next phase of AI infrastructure spending will shift toward faster, lower-power optical links inside data centers. Because CRDU provides concentrated, leveraged exposure to a single optical-connectivity name, the sector-wide bid had an amplified effect on the fund.

AI Infrastructure and Silicon Photonics Demand

Underpinning the rally is persistent demand for higher-bandwidth connectivity as hyperscalers and "NeoCloud" providers scale AI clusters. Credo's active electrical cables (AECs), optical DSPs, and silicon-photonics products sit directly in this buildout. The company reported fiscal first-quarter 2027 revenue of $479 million, up 114.7% year over year and its seventh consecutive quarter of triple-digit growth, and it guided to more than 85% revenue growth for the full fiscal year. This fundamental backdrop kept buyers engaged as the optical complex strengthened.

Analyst Coverage and the Co-Packaged Optics Theme

Fresh sell-side commentary added fuel. Mizuho initiated coverage of Tower Semiconductor with an Outperform rating and a $300 price target, framing silicon photonics as central to scaling data center bandwidth over the next decade, while Citi highlighted co-packaged optics (CPO) as a key "next wave" of AI infrastructure. Although these notes named other companies, they reinforced the broader thesis that optical interconnect suppliers—including Credo—stand to benefit, lifting sentiment across the group that CRDU tracks.

Which Holdings Contributed Most

CRDU does not hold a diversified basket of individual stocks. As a single-stock leveraged ETF, its performance is driven almost entirely by the daily move in Credo Technology shares, achieved through derivatives such as swaps and options. Accordingly, CRDO's intraday advance of roughly 7.6%—from a prior close near $195.97 to about $210.92—was the sole meaningful driver of the fund's 15.55% gain, with the 2x leverage factor and daily rebalancing explaining the difference between the two percentages.

Market Context and Trading Activity

The fund's move aligned closely with peer optical and semiconductor names, confirming a thematic rather than idiosyncratic catalyst. Broader semiconductor and AI-adjacent stocks also firmed, and pre-market strength in optical, memory, and Neocloud names carried into the regular session. CRDU has traded on elevated volume in recent sessions relative to its early average, consistent with heightened interest in the leveraged AI-connectivity trade. The gain also continued a multi-day recovery in both CRDO and CRDU, which had pulled back earlier in the month alongside the broader AI infrastructure complex.

What Comes Next for CRDU

Investors should monitor several factors. First, hyperscaler capital-expenditure plans remain the central swing factor for optical-connectivity demand; any moderation in AI spending could quickly reverse sentiment. Second, Credo's ramp of 1.6T AECs and optical DSPs, plus its target of more than $600 million in fiscal 2027 optical revenue, will test whether execution keeps pace with expectations. Third, customer concentration is a known risk—Credo's two largest end customers accounted for about 61% of recent quarterly revenue. Finally, because CRDU resets its 2x exposure daily, returns over periods longer than a single trading day can diverge meaningfully from two times the underlying stock's performance, and the fund carries elevated volatility and decay risk that buy-and-hold investors should understand.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. The featured bots represent those performing best in the present environment, giving traders a convenient way to explore algorithm-driven ideas across ETFs and equities.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRDU

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CRDU's RSI Oscillator climbs out of oversold territory

The RSI Indicator for CRDU moved out of oversold territory on September 16, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 5 similar instances when the indicator left oversold territory. In 5 of the 5 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on CRDU as a result. In 16 of 17 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for CRDU just turned positive on September 21, 2026. Looking at past instances where CRDU's MACD turned positive, the stock continued to rise in 11 of 11 cases over the following month. The odds of a continued upward trend are 90%.

Following a +3.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDU advanced for three days, in 57 of 61 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CRDU broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRDU entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times (200%) the daily performance of the common shares of CRDO. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide two times leveraged exposure to the daily performance of CRDO. It is non-diversified.
View a ticker or compare two or three
CRDU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
Investment Managers Series Trust II803 West Michigan StreetMilwaukee
Phone
(414) 299-2295
Web
N/A
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.